Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.

Zhang, Guang-Sen

Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. [electronic resource] - American journal of hematology Apr 2006 - 242-55 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0361-8609

10.1002/ajh.20542 doi


Antineoplastic Agents--pharmacology
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Apoptosis--drug effects
Benzamides
Bone Marrow Cells--enzymology
Caspase 3
Caspase Inhibitors
Caspases--metabolism
Celecoxib
Cyclin D1--metabolism
Cyclin E--metabolism
Cyclin-Dependent Kinase Inhibitor p16--metabolism
Cyclin-Dependent Kinase Inhibitor p27
Cyclooxygenase 2--biosynthesis
Cyclooxygenase Inhibitors--pharmacology
Dose-Response Relationship, Drug
Down-Regulation--drug effects
Drug Synergism
Enzyme Activation--drug effects
Enzyme Inhibitors--pharmacology
G1 Phase--drug effects
Gene Expression Regulation, Enzymologic--drug effects
Gene Expression Regulation, Leukemic--drug effects
Humans
Hydroxyurea--pharmacology
Imatinib Mesylate
Interleukin-1--pharmacology
Intracellular Signaling Peptides and Proteins--metabolism
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Membrane Proteins--antagonists & inhibitors
Piperazines--pharmacology
Pyrazoles--pharmacology
Pyrimidines--pharmacology
S Phase--drug effects
Sulfonamides--pharmacology